In The News

Why Psychedelic Drugs May Become a Key Treatment for PTSD and Depression

Funders at Johns Hopkins Shape The Future of Psychedelic Research

Canada’s SAP Expansion Signals a Step Forward for Psychedelics

New compound could make microdosing “heart-safe”

Mydecine submits pre-IND briefing package to FDA for MYCO-001 smoking cessation clinical trial

Psychedelic Stocks Remain Solid Long-Term Investment: Mydecine CEO On Industry Outlook

Psychedelic Business Spotlight — January 28

Mydecine Is Poised To Provide A Psychedelic Specialized Program Throughout Canada

The Future of Psilocybin Therapy with Josh Bartch, CEO of Mydecine Innovation Group on Gamechangers®

Mydecine’s Dr. Rick Barnett On Psychedelics In The Fight Against Addiction